Sekundære effektparametre Bondronat 50 mg viste i sammenligning med placebo en statistisk signifikant forbedring i knoglesmertescore.
Secondary Efficacy Endpoints A statistically significant improvement in bone pain score was shown for Bondronat 50 mg compared to placebo.